Emergent BioSolutions (NYSE: EBS)
Emergent BioSolutions Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Emergent BioSolutions Company Info
Emergent BioSolutions makes the only FDA-approved anthrax vaccine.
News & Analysis
Why Emergent BioSolutions Stock Blasted Higher Today
Why Emergent BioSciences Stock Plummeted Today
Investing in Vaccine Stocks
Learn about the companies that are manufacturing vaccines and what you should know before investing in vaccine stocks.
Why Emergent BioSolutions Stock Is Skyrocketing Today
Concerns about the mpox outbreak are causing Emergent BioSolutions' shares to jump.
Why Emergent BioSolutions Stock Is Tumbling Today
The healthcare stock will soon be booted from an index tracked by several ETFs.
Why Emergent BioSolutions Stock Dived by 9% Today
Investors didn't greet news of the CEO's departure warmly.
Better Recovery-Story Buy: Emergent BioSolutions or Invitae?
Both of these stocks have plummeted more than 50% over the past year.
Is Emergent BioSolutions Stock a Buy Now?
The deluge of bad news seems to be over, and a recovery could be in the works.
Valuation
Earnings Transcripts
Emergent BioSolutions (EBS) Q4 2024 Earnings Call Transcript
EBS earnings call for the period ending December 31, 2024.
Emergent BioSolutions (EBS) Q3 2024 Earnings Call Transcript
EBS earnings call for the period ending September 30, 2024.
Emergent BioSolutions (EBS) Q2 2024 Earnings Call Transcript
EBS earnings call for the period ending June 30, 2024.
Emergent BioSolutions (EBS) Q1 2024 Earnings Call Transcript
EBS earnings call for the period ending March 31, 2024.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.